A,B) Changes in CD19+ B cell frequency before and after the first... | Download Scientific Diagram
Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis | Neurology Neuroimmunology & Neuroinflammation
Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland | PLOS ONE
Mean (± SD) plasma rituximab concentration versus time profiles after... | Download Scientific Diagram
Baseline characteristics at first RTX infusion in all MS, RRMS and PMS... | Download Table
Clinical courses after RTX infusion in children with refractory NS | Download Table
Rituximab abrogates aquaporin-4–specific germinal center activity in patients with neuromyelitis optica spectrum disorders | PNAS
Inclusion flow chart. Interval, prolonged time periods between last... | Download Scientific Diagram
Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus | Annals of the Rheumatic Diseases
A New Schedule of CHOP/Rituximab Plus Granulocyte-Macrophage Colony-Stimulating Factor Is an Effective Rescue for Patients with Aggressive Lymphoma Failing Autologous Stem Cell Transplantation - Biology of Blood and Marrow Transplantation
Rituximab-induced lung disease: a systematic literature review | European Respiratory Society
Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration - ScienceDirect
Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor–dependent idiopathic nephrotic syndrome - ScienceDirect
Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration - ScienceDirect
PV | RITUXAN® (rituximab) Dosing & Infusion Resources
A, ECG prior to RTX infusion. B, Occurrence of PVC during RTX infusion.... | Download Scientific Diagram
Comparison of Switching from the Originator Rituximab to the Biosimilar Rituximab GP2013 or Re‑Treatment with the Originator Rituximab in Patients with Active Rheumatoid Arthritis: Safety and Immunogenicity Results from a Multicenter, Randomized,
Frontiers | Rituximab Therapy for Primary Sjögren's Syndrome
Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar | SpringerLink
Clinical courses after RTX infusion in children with refractory NS | Download Table
Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar | SpringerLink
Baseline characteristics at first RTX infusion in all MS, RRMS and PMS... | Download Table
